Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) announces that Chief Medical Officer, Dr. Omar Manejwala, will present at the American Health Insurance Plans' National Conference on Medicare, Medicaid, and Dual Eligibles on September 22, 2021, at 12:45 p.m. EST. His presentation will focus on the role of digital therapeutics in addressing health disparities among Medicaid populations. Dr. Manejwala emphasizes the need for tailored digital solutions to improve access and health outcomes for underserved groups, highlighting significant growth in digital health during the pandemic.

DarioHealth Corp. (Nasdaq: DRIO) has been selected by PeopleOne Health as its preferred digital behavioral health solution starting September 2021. This partnership aims to enhance mental health support for patients through AI-driven assessments and integrated digital tools. Rick Anderson, President of North America at DarioHealth, emphasized the importance of modern solutions for patient care, highlighting this agreement's validation of Dario's value in point-of-care settings. The collaboration underscores Dario's expansion in the provider market and its commitment to holistic health management.

DarioHealth Corp. (Nasdaq: DRIO) reported a strong Q2 2021, with revenues of $5.3 million, growing 46% sequentially and 194% year-over-year. The company expanded its digital therapeutics offerings through acquisitions, enhancing its sales pipeline to over $900 million. Gross profit margins improved to 49.4%, reflecting growth in their SaaS model. However, the operating loss increased to $18 million, a 337% rise from the previous year. Cash reserves stood at $63.9 million, positioning Dario for ongoing growth amid increased operating expenses.

DarioHealth Corp. (Nasdaq: DRIO) announced a study at the ADCES conference showcasing the effectiveness of its personalized digital therapeutics platform. The research involved 3,609 members with Type 2 diabetes, showing a 19% reduction in high blood glucose readings compared to the control group. A notable 42% reduction was observed in non-insulin users. This study emphasizes the importance of real-time personalized interventions in influencing positive lifestyle changes and improving clinical outcomes.

DarioHealth Corp. (Nasdaq: DRIO) will announce its second quarter financial results for the period ending June 30, 2021 on August 16, 2021. A conference call and webcast will take place at 8:30 AM EDT, featuring CEO Erez Raphael, President Rick Anderson, and CFO Zvi Ben-David.

Participants should join the call 10 minutes early. A replay will be available until September 16, 2021. DarioHealth is a leader in digital therapeutics, offering solutions for chronic conditions like diabetes and hypertension.